Clinical trials
Observational Disease trials in the United Kingdom
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
65 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2006 | 1 |
| 2009 | 1 |
| 2010 | 2 |
| 2012 | 3 |
| 2013 | 2 |
| 2014 | 1 |
| 2015 | 3 |
| 2016 | 3 |
| 2017 | 2 |
| 2018 | 3 |
| 2019 | 8 |
| 2020 | 1 |
| 2021 | 7 |
| 2022 | 5 |
| 2023 | 5 |
| 2024 | 5 |
| 2025 | 6 |
| 2026 | 7 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 24 |
| Recruiting | 16 |
| Unknown status | 12 |
| Active, not recruiting | 7 |
| Withdrawn | 2 |
| Enrolling by invitation | 2 |
| Terminated | 1 |
| Suspended | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Imperial College London | 5 |
| University of Edinburgh | 5 |
| University of Oxford | 3 |
| King's College London | 2 |
| University College, London | 2 |
| University Hospital Southampton NHS Foundation Trust | 2 |
| University of Dundee | 2 |
| Alder Hey Children's NHS Foundation Trust | 1 |
| AstraZeneca | 1 |
| Barts & The London NHS Trust | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Disease | 65 |
| Neoplasms | 7 |
| Asthma | 5 |
| Dementia | 5 |
| Pulmonary Disease, Chronic Obstructive | 5 |
| Lung Diseases, Interstitial | 4 |
| Lung Neoplasms | 4 |
| Cognitive Dysfunction | 3 |
| Dyspnea | 3 |
| Pneumonia | 3 |
Trials
Showing 1 to 25 of 65. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.